In vitro and in vivo studies displayed that ANRIL overexpression sustains MM cell growth and resistance to bortezomib-induced apoptosis by interacting with the histone-methyltransferase enzyme EZH2 that epigenetically silences PTEN and mediates chemoresistance [124]. Here, CDKN2B-AS1 is linked to Miyoshi myopathy.